Related Experiment Videos
Cytogenetic studies in patients treated with penicillamine
Mutation Research
|August 1, 1979
Summary
Penicillamine treatment for rheumatoid arthritis did not cause chromosome damage in patients. Cytogenetic studies, including the micronucleus test, found no evidence of harmful effects on bone-marrow cells, even during adverse events like low blood cell counts.
Area of Science:
- Rheumatology
- Clinical Cytogenetics
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring long-term management.
- Penicillamine is a disease-modifying antirheumatic drug (DMARD) used in RA treatment.
- Potential adverse effects of penicillamine, including hematological issues, necessitate safety monitoring.
Purpose of the Study:
- To investigate the potential cytogenetic toxicity of penicillamine in rheumatoid arthritis patients.
- To assess whether penicillamine induces chromosomal aberrations or micronuclei formation in bone marrow cells.
Main Methods:
- Bone-marrow cells were collected from 11 rheumatoid arthritis patients undergoing penicillamine therapy.
- Cytogenetic analysis was performed, including the micronucleus test.
- Structural chromosomal aberrations were quantified.
Main Results:
- No significant increase in micronuclei formation was observed, indicating no clastogenic effect.
- The number of structural chromosomal aberrations in bone-marrow cells remained within normal limits.
- Findings were consistent even in a patient experiencing granulocytopenia and thrombocytopenia.
Conclusions:
- Penicillamine treatment does not appear to exert a chromosome-damaging effect in rheumatoid arthritis patients.
- The drug's safety profile regarding genotoxicity is supported by these cytogenetic findings.
- Further monitoring for hematological side effects remains important despite the absence of cytogenetic damage.